hVIVO is the new name for Retroscreen Virology

Retroscreen Virology, a leading life sciences human disease model company, is excited to announce it has changed its corporate name to hVIVO, a name that relays its broader vision and pioneering efforts using human studies to revolutionize drug development.

Kym Denny, Chief Executive Officer, stated: “I am delighted to announce the formal launch of our new Company name hVIVO. Human volunteers are at the heart of all we do. Changing the Company name to hVIVO plc reflects the revolutionary step of using human models of disease to develop treatments for humans. A pioneering concept in drug testing deserves a pioneering name to best describe it and we chose hVIVO.”

The ‘h’ celebrates the human aspect of the organisation’s unique process to accelerate drug development. Humans, in the shape of willing clinical trial volunteers, provide a living sample that are utilised in a clinically controlled environment in the Company’s pioneering Human Challenge Model.

‘VIVO’ represents the science of clinical testing on living organisms and, in this case, the human sample which is at the very heart of the business.

This name change to hVIVO reflects the organisation’s expanded vision and a new human dimension to the way new therapeutic and diagnostics are discovered and developed.

Retroscreen Virology Group plc changes to hVIVO plc, and the main trading subsidiary, Retroscreen Virology Limited, changes to hVIVO Services Limited.

For more information, visit the new website at www.hvivo.com .